Aethoxysklerol® shows very good effects in the treatment of spider veins and reticular varices
This was most recently again investigated and proven in the FDA-approved, multi-center, randomized, double-blind EASI study5. The primary criterion of this clinical trial was to show the ‘improvement of veins’, comparing treatment with lauromacrogol 400 (polidocanol), sodium tetradecyl sulfate and isotonic saline (placebo). Twelve weeks after the last injection the treatment success rate for polidocanol was 96%. Significantly more patients were satisfied with polidocanol (84%) in comparison with sodium tetradecyl sulfate (64%).
Another long-term study conducted in various Australian hospitals, evaluated the complications and effectiveness of lauromacrogol 400 (polidocanol). The investigators came to the conclusion that the effectiveness of polidocanol is superior to sodium tetradecyl sulfate and hypertonic saline. In addition, as most investigators observed, it leads to less complications and is less painful.6
Aethoxysklerol® is highly effective for the treatment of 1st and 2nd degree hemorrhoidal disease
A prospective randomized trial7 compared the efficacy and side effects of Aethoxysklerol® 3% with those of 5% phenol in oil in the treatment of 1st and 2nd degree hemorrhoidal disease.
Both agents were injected submucously into the surrounding tissue of the supply arteries just above the origin of the hemorrhoids. The results showed that 88% of the lauromacrogol 400 (polidocanol) group were successfully treated after one treatment and even 97% after two treatments. In conclusion, both agents were equally effective. However, polidocanol showed much fewer side effects than phenol (such as pain, necrosis and ulceration).
Sclerotherapy is known to have few side effects if it is performed properly. These complications include hematoma, allergic reactions, necrosis, skin hyperpigmentation, matting and superficial thrombophlebitis.
For a complete overview of side effects and contraindications, please download the Summary of Product Characteristics.
Please note: Not all concentrations and indications are available in every country. Trade names may vary from country to country. Information on this website is based on German Summary of Product Characteristics.
Please refer to your national marketing authorization.
5 Rabe E. et al. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulfate and isotonic saline (EASI study). Phlebology 2010; 25: 124-131.
6 Conrad P. et al. The Australian Polidocanol (Aethoxysklerol) Study Results at 2 Years. Dermatol Surg 1995; 21: 334-336.
7 Akerud L. Sclerotherapy of Haemorrhoids. A prospective Randomised Trial of Polidocanol and Phenol in Oil. Coloproctology 1995; 17: 73-86.